drugset / Trial / NCT01561027

Crossover Study of CNV1014802 in Subjects With Neuropathic Pain From Lumbosacral Radiculopathy

NCT01561027

Phase 2 Completed 82 enrolled Biogen
RandomizedCrossoverTriple-blindTreatment

Summary

The study is a randomized, double blind, cross-over study to evaluate the safety and efficacy of CNV1014802 in subjects with neuropathic pain from lumbosacral radiculopathy.

Timeline

Start
2011-04-30
Primary completion
2012-06-30
Completion
2012-08-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Vixotrigine Small molecule 350 mg

Indications